How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,474 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. First Generation Sulfonylurea

First Generation Sulfonylurea First Generation Sulfonylurea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 First Generation (...) Sulfonylurea First Generation Sulfonylurea Aka: First Generation Sulfonylurea , Tolbutamide , Tolazamide , Chlorpropamide , Acetohexamide From Related Chapters II. Indications Replaced by agents for the management of III. Preparations Acetohexamide (Dymelor) Dose: 500-750 mg qd or divided ($14) Chlorpropamide (Diabinese) Dose: 100-250 up to 750 mg qd/bid Antidiuretic effect (used in ) Tolazamide (Tolinase) Dose: 250-500 mg PO qd or divided ($2.81) Tolbutamide (Orinase) Dose: 1000-2000mg qd or divided bid

2018 FP Notebook

2. Sulfonylureas in Diabetes: Sweet on the Heart or Surrogate Charlatan?

HbA1c, not patient-oriented outcomes. 1-5 ? Largest RCT for patient outcomes (n=409), ~5 years, tolbutamide versus placebo: 6,7 o Non-significant: All-cause mortality (14.7% versus 10.2%), myocardial infarction (13.7% versus 10.7%). o Significant increase: Cardiovascular (CV) mortality (12.7% versus 4.9%), Number Needed to Harm (NNH)=13. o Limitations: Possible randomization imbalance, smoking not included in baseline demographics, first generation sulfonylurea. Sulfonylurea versus metformin: ? RCT (...) Sulfonylureas in Diabetes: Sweet on the Heart or Surrogate Charlatan? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,600 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca

2018 Tools for Practice

3. Sulfonylureas can be considered safe for those with type 2 diabetes

is contraindicated or not tolerated. Sulfonylureas are also recommended as add-on therapy to metformin (or other first-choice drug) if that drug alone has not adequately controlled sugar levels. It is also an option as part of triple drug therapy. What are the implications? These findings provide reassuring evidence that second and third generation sulfonylureas are not associated with increased rates of death, heart attack or stroke. These trials were non-randomised and ran for up to 11 years, meaning (...) diabetes. Sulfonylureas are an inexpensive group of drugs frequently used in the treatment of type 2 diabetes. They work to improve blood sugar control by increasing insulin release from the pancreas. It is estimated that 20-30% of people with type 2 diabetes in developed countries take a newer second or third generation sulfonylurea, such as glipizide or glimepiride. There is conflicting evidence about the safety of these drugs regarding deaths and cardiovascular outcomes. Therefore, this study aimed

2019 NIHR Dissemination Centre

4. Sulfonylureas can be considered safe for those with type 2 diabetes

is contraindicated or not tolerated. Sulfonylureas are also recommended as add-on therapy to metformin (or other first-choice drug) if that drug alone has not adequately controlled sugar levels. It is also an option as part of triple drug therapy. What are the implications? These findings provide reassuring evidence that second and third generation sulfonylureas are not associated with increased rates of death, heart attack or stroke. These trials were non-randomised and ran for up to 11 years, meaning (...) diabetes. Sulfonylureas are an inexpensive group of drugs frequently used in the treatment of type 2 diabetes. They work to improve blood sugar control by increasing insulin release from the pancreas. It is estimated that 20-30% of people with type 2 diabetes in developed countries take a newer second or third generation sulfonylurea, such as glipizide or glimepiride. There is conflicting evidence about the safety of these drugs regarding deaths and cardiovascular outcomes. Therefore, this study aimed

2018 NIHR Dissemination Centre

5. Second Generation Sulfonylurea

Sulfonylurea Second Generation Sulfonylurea Aka: Second Generation Sulfonylurea , Glipizide , Glyburide , Glimepiride , Amaryl , Sulfonylurea Drug Interactions Causing Hypoglycemia From Related Chapters II. Indications: Type II Diabetes Mellitus (early, phase 1-2) Better effect in lean patients Consider when <9% Second-line to in most patients Consider as first-line in specific cohorts Consider when post-prandial 200 to 300 mg/dl Consider when Type II with , polydipsia III. Contraindication (applies (...) Second Generation Sulfonylurea Second Generation Sulfonylurea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Second Generation

2018 FP Notebook

6. Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

: November 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Sotagliflozin dose 1 Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day Drug: sotagliflozin (SAR439954) Pharmaceutical form: tablet Route of administration: oral Drug: metformin Pharmaceutical form: tablet Route of administration: oral Drug: sulfonylurea Pharmaceutical form: tablet (...) Drug: sulfonylurea Pharmaceutical form: tablet Route of administration: oral Placebo Comparator: Placebo Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day Drug: placebo Pharmaceutical form: tablet Route of administration: oral Drug: metformin Pharmaceutical form: tablet Route of administration: oral Drug: sulfonylurea Pharmaceutical form: tablet Route of administration: oral Outcome Measures Go to Primary

2018 Clinical Trials

7. Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria: Participant must be ≥18 years of age at the time of signing the informed consent. Participants with type 2 diabetes mellitus. Diabetes diagnosed at least 1 year before screening. Participants on metformin alone or in combination with sulfonylurea (SU), for at least 3 months prior (...) Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2018 Clinical Trials

8. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff (...) level of 7% was used as the threshold for moving from first- to second-line therapy, and 7.5% was used for moving to third-line therapy. Location/setting Germany/primary care. Methods Analytical approach: A published state-transition model (the Cardiff Diabetes Model) was adapted to estimate the cost-effectiveness of the treatment pathways, over 40 years. The model assessed three lines of treatment, which differed in second-line therapy only. The authors stated that the perspective

2012 NHS Economic Evaluation Database.

9. Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

. ClinicalTrials.gov Identifier: NCT03066830 Recruitment Status : Active, not recruiting First Posted : February 28, 2017 Last Update Posted : November 9, 2018 Sponsor: Sanofi Information provided by (Responsible Party): Sanofi Study Details Study Description Go to Brief Summary: Primary Objective: To demonstrate the superiority of sotagliflozin 400 mg versus placebo on Hemoglobin A1c (HbA1c) reduction at Week 26 in patients with type 2 diabetes (T2D) who have inadequate glycemic control with a sulfonylurea alone (...) Inadequate Glycemic Control on a Sulfonylurea Alone or With Metformin Actual Study Start Date : February 24, 2017 Estimated Primary Completion Date : May 2019 Estimated Study Completion Date : May 2019 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Sotagliflozin A dose of sotagliflozin will be administered as 2 tablets, once daily, before the first meal of the day Drug: Sotagliflozin

2017 Clinical Trials

10. Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 20 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes with HbA1c 7.5% - 9.0% at screening visit Male or female between 20 and 75 years of age Patients taking sulfonylurea (glimepiride 1~8mg or gliclazide 30~120 mg or equivalent dose) and metformin (≥ 1000 mg (...) Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

11. Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

12. Effect of sulfonylurea tribenuron methyl herbicide on soil Actinobacteria growth and characterization of resistant strains (PubMed)

, as tribenuron methyl disappeared, two compounds were detected with increased concentrations. These by-products appeared to be persistent and were not degraded either chemically or by the studied strains. Based on these observations, we suggested that bacterial activity on carbon substrates could be directly involved in the partial breakdown of tribenuron methyl, by generating the required acidity for the first step of the hydrolysis. Such a process would be interesting to consider in bioremediation (...) Effect of sulfonylurea tribenuron methyl herbicide on soil Actinobacteria growth and characterization of resistant strains Repeated application of pesticides disturbs microbial communities and cause dysfunctions on soil biological processes. Granstar® 75 DF is one of the most used sulfonylurea herbicides on cereal crops; it contains 75% of tribenuron-methyl. Assessing the changes on soil microbiota, particularly on the most abundant bacterial groups, will be a useful approach to determine

Full Text available with Trip Pro

2017 Brazilian Journal of Microbiology

13. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy (PubMed)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy Diabetes mellitus is a chronic disease related to a significant impact in both epidemiologic and economic terms. In Italy, around 3.6 million people are affected by diabetes and this number is expected to increase significantly in the next few years. As recommended by current national and international guidelines, metformin (Met) is prescribed as first-line (...) pharmacological treatment, and many pharmacological alternatives are available for patients uncontrolled with Met monotherapy. Despite the availability of many innovative oral antidiabetic drugs (OADs), such as dipeptidyl peptidase 4 inhibitors (DPP4-i) and its first-in-class sitagliptin (SITA), which entered the Italian market in the last 10 years, their usage is consistently lower than traditional drugs such as sulfonylureas (SUs). In fact, due to higher acquisition costs, the prescription of innovative

Full Text available with Trip Pro

2017 ClinicoEconomics and Outcomes Research: CEOR

14. First Generation Sulfonylurea

First Generation Sulfonylurea First Generation Sulfonylurea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 First Generation (...) Sulfonylurea First Generation Sulfonylurea Aka: First Generation Sulfonylurea , Tolbutamide , Tolazamide , Chlorpropamide , Acetohexamide From Related Chapters II. Indications Replaced by agents for the management of III. Preparations Acetohexamide (Dymelor) Dose: 500-750 mg qd or divided ($14) Chlorpropamide (Diabinese) Dose: 100-250 up to 750 mg qd/bid Antidiuretic effect (used in ) Tolazamide (Tolinase) Dose: 250-500 mg PO qd or divided ($2.81) Tolbutamide (Orinase) Dose: 1000-2000mg qd or divided bid

2015 FP Notebook

15. SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Sulfonylurea on Type 2 Diabetes With NAFLD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02649465 Recruitment Status : Recruiting First Posted : January 7, 2016 Last Update Posted : January 7, 2016 See Sponsor: Kanazawa (...) SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. SGLT2 Inhibitor Versus

2016 Clinical Trials

16. Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (LixiRam) The safety and scientific validity of this study is the responsibility of the study sponsor

2016 Clinical Trials

17. Could Metformin be the First Anti-Aging Drug?

colleagues at the Institute for Aging Research are looking to make a cheap, generic, widely used drug—metformin—the first to be Food and Drug Association (FDA)-approved for the indication of aging. Metformin is an oral biguanide antidiabetic medication that has been used for over 50 years. It is commonly prescribed as a first-line treatment for type 2 diabetes mellitus and often in combination with other antidiabetic medications including insulin. Metformin reduces blood glucose levels by preventing (...) Could Metformin be the First Anti-Aging Drug? Could Metformin be the First Anti-Aging Drug? – Clinical Correlations Search Could Metformin be the First Anti-Aging Drug? February 11, 2016 6 min read By Amy Shen Tang, MD P eer Reviewed “I would pay you if you took it away from me. I’d try to buy it back,” said Irving Kahn, the late Wall Street [1]. Mr. Kahn, who founded Kahn Brothers Group, Inc. with his sons more than 40 years ago, took an active role as chair of his company until his passing

2016 Clinical Correlations

18. Second Generation Sulfonylurea

Sulfonylurea Second Generation Sulfonylurea Aka: Second Generation Sulfonylurea , Glipizide , Glyburide , Glimepiride , Amaryl , Sulfonylurea Drug Interactions Causing Hypoglycemia From Related Chapters II. Indications: Type II Diabetes Mellitus (early, phase 1-2) Better effect in lean patients Consider when <9% Second-line to in most patients Consider as first-line in specific cohorts Consider when post-prandial 200 to 300 mg/dl Consider when Type II with , polydipsia III. Contraindication (applies (...) Second Generation Sulfonylurea Second Generation Sulfonylurea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Second Generation

2015 FP Notebook

19. Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)

Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) (SuResponsSUR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02624830 Recruitment Status : Unknown Verified December 2015 by Haukeland University Hospital. Recruitment status was: Enrolling by invitation First Posted : December 8, 2015 Last (...) of sulfonylurea and glucose control in children with diabetes due to mutations in ABCC8 that have been switched from insulin injections to sulfonylurea tablets. Condition or disease Intervention/treatment Phase Permanent Neonatal Diabetes Mellitus Drug: Sulfonylurea Phase 4 Detailed Description: Neonatal diabetes mellitus is a rare, monogenic form of diabetes occurring during the first 6-9 months of life characterized by hyperglycemia requiring exogenous insulin therapy. The estimated incidence is 1 per 12000

2015 Clinical Trials

20. Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

to sulfonylurea tablets. Condition or disease Intervention/treatment Phase Permanent Neonatal Diabetes Mellitus Drug: Sulfonylurea Phase 4 Detailed Description: Neonatal diabetes mellitus is a rare, monogenic form of diabetes occurring during the first 6-9 months of life characterized by hyperglycemia requiring exogenous insulin therapy. The estimated incidence is 1 per 12000 newborns. Although homozygous or compound heterozygous mutations in the genes IPF1 or GCK were the first genetic causes of this disease (...) deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 9 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Permanent diabetes due to a mutation in KCNJ11 (KIR6.2) Patients successfully transferred from insulin to sulfonylurea Transferred

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>